NOAC dosage for patients undergoing cardioversion for atrial fibrillation

Join Professor John Camm and Dr Michael Ezekowitz for a discussion of the optimal anticoagulation strategy for a real-life patient case undergoing cardioversion for atrial fibrillation.

[template part=”video”]

Register your email and provide your feedback

To help measure the effectiveness of this NOAC Education module, please enter your email below to take part in a short follow-up survey

[template part=”speaker”]

Topic

In this video, filmed at ACC 2018, Professor John Camm and Dr Michael Ezekowitz discuss the case of a 78-year old male with well-controlled hypertension who presented to the emergency department with palpitations. Discover the anticoagulation approach taken for this patient after an EKG confirmed atrial fibrillation and a cardioversion was planned. The risks and benefits of warfarin versus non-vitamin K oral anticoagulants (NOACs) are also explored, before an in-depth discussion into the optimal NOAC dosage before and after cardioversion.

[template part=”details”]